YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Clinical Pharmacokinetics of Vancomycin in Gastric Cancer Patients

위암 환자에서 반코마이신의 임상약물동태

  • Published : 1997.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study was to determine pharmacokinetic parameters of vancomycin using two point calculation(TPC) and Bayesian methods in 16 Korean normal volunteers and 15 g astric cancer patients. Nonparametric expected maximum(NPEM) algorithm for calculation of population pharmacokinetic parameter was used, and these parameters were applied for clinical pharmacokinetic parameters by Bayesian analysis. Vancomycin was administered 1.0g every 12 hrs for 3 days by IV infusion over 60 minutes. The volume of distribution(Vd), elimination rate constant(Kel) and total body clearance(CLt) of vancomycin in normal volunteers using TPC method were $0.34{\pm}0.06 L/kg,\; 0.19{\pm}0.01 hr^{-1}$ and $4.08 {\pm} 0.93 L/hr$, respectively, The Vd, Kel and CLt of vancomycin in gastric cancer patients using TPC method were $0.46 {\pm} 0.06 L/kg, 0.17{\pm}0.02 hr^{-1}$ and $4.84 {\pm} 0.57 L/hr$ respectively. There were significant differences(p<0.05) in Vd. Kel and CLt between normal volunteers and gastric cancer patients. Polpulation pharmacokinetic parameter, the slope(KS) of the relationship beetween Kel versus creatinine Clearance, and the Vd were $0.00157{\pm}0.00029(hr{\cdot}mL/min/1.73m^2)^{-1},\; 0.631 {\pm} 0.0036 L/kg$ in gastric cancer patients using NPEM algorithm respectively. The Vd and Kel were $0.63{\pm}0.005 L/kg, 0.15 {\pm}0.027 hr^{-1}$ for gastric cancer patients using Bayesian method. There were significant differences(p<0.05) in vancomycin pharmacokinetics between Bayesian and TPC methods. It is considered that the population parameter in the patient population is necessary for effective Bayesian method in clinical pharmacy practise.

Keywords

References

  1. Rev. Infect. Dis. v.3 The antibacterial action of vancomycin Watanakunakorn, C.
  2. J. Am. Chem. Soc. v.105 Vancomycin structure and trasformation Harris, C. M.;Kopecka, H.
  3. Ann, Intern Med. v.88 Vancomycin revisited Cook, F. V.;Farrar, W. W.
  4. J. Antimacrob. Chemother. v.14 Vancomycin therapy of severe staphylococcal infections Kirby, W. M. M.
  5. Antibiotics v.3 Vancomycin therapy for methcillin-resistant staphylococcus sureus Sorrell, T. C.
  6. J. Infect. Dis. v.147 Vancomcin treatment of bacteremia causedd by oxacillin resistant staphylococcus aureus : comparison with β-lactam antibiotics treatment of vacteremia caused by oxocillin-sensitive staphylococcus aureus Craven, D. E.
  7. J. Antimicrob. Chemother. v.11 Vancomycin therapy of oxacillin-resistant staphylococcus epidermidis in fections Klastersky, j.
  8. Ann, Intern. Med. v.97 Treatment of infections due to methicillin-resistant staphylococcus aureus Watanakunakorn, C.
  9. J. Kor. Soc. Hosp. Pharm. v.4 Theophylline clearance of Korean population in comparison with American Kim, J. K.;Yoo, D. S.;Shim, H. T.;Kim, N. D.;Kim, J. K.;Kim, G. Y.;Kim, Y. K.
  10. J. Kor. Med. Associ. v.31 Development of therapeutic drug monitoring program Shin, H. T.
  11. Clim. Pharm. v.3 Bayesian approaches in pharmacokinetic decision making Schumacher, G. E.;Barr, J. T.
  12. Clin. Pharmacol. Ther. v.37 A Bayesian method of aminoglycoside dosing Burton, M. E.;Vrater, D C.;Chen, P. S.
  13. Drug. Intell. Clin. Pharm. v.22 validation of te use of Bayesian analysis in the optimization of gentamicin therpy from the commencement of dosing Chrystn, H.
  14. Antimicrob. Agents Chemother. v.34 Application of a bayesian method to monitor and adjust van-comycin dosage regimens Hurst, A.;Yoshinaga, M.;Mitani, G.;Foo, K.;Jelliffe, R.;Harrison, E.
  15. Clin. Pharmacokinet. v.21 Individualizing gentamicin dosage regimens. A comparative review of selected methods. Data fitting methods and monitoring strategies Jelliffe, R. W.;Iglesias, T.;Hurst, A. K.
  16. Biometrics v.31 Bayesian approach to the analysis of nonlinear models: implementation and evaluation Katz, D.
  17. Proceedings of the fifth anual symposium on computer applications in medical care An aminoglycoside dosing program using a Bayesian algorithm Perline, Peck, C. C.;Nichols, L.
  18. J. Pharm. Sci. v.71 Bayesian individualization of pharmacokinetics. Simple implementation and comparison with non-Bayesian methods Sheiner, L. B.;Beal, S. L.
  19. Clin. Pharmacokinet. v.22 bayesian parameter estimation and population pharmacokinetics Thomson, A. H.;Whiting, B.
  20. J. Pharmacokinet. Biopharm. v.4 Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients Sawchuk, R. J.;Zaske, D. E.
  21. Estimating interindividual pharmacokinetic variability. In variability of drug therapy: description, estimation,a dn control Steimer, J. L.;Mallet, A.;Mentre, F.
  22. Population models. In statistical methodology in the pharmaceutical sciences Racine-Poon, A.;Smith, A. F. M.
  23. Drug Metab. Rev. v.16 Population pharmacokinc data and parameter estimation based on their first two statistical moments Beal, S.
  24. Technical report of Division of Clinical Pharmacology Asymptotic properties of optimizaiton estimates for the independent net identically distributedd case with application to extended least-squares estimate Beal, S.
  25. Technical report of Division of Clinical Pharmacology NONMEM users guide-part 1: users basic guide Beal, S.;Sheiner, L.
  26. Biometrika v.73 A maximum likelihood estimation method for random coefficient regression models Mallet, A.
  27. J. Pharmacokinet. biopharm. v.16 Nonparametric maxmum likelihood estimatio for population pharmacokinetics, with application to cyclosporine Mallet, A.;pMentre, F.;Steimer, J. L.;Lookiec, F.
  28. J. Pharmacokinet. Biopharm. v.16 Nonparametric maxmum likelihood estimation for populatin pharmacokinetics, with application to cyclosporine Mallet, A.;Mentre, F.;Steimer, J. L.;Lookiec, F.
  29. Clin Pharmacokinet. v.23 Population pharmacokinetics of gentamicin: use of the nonparametric expectation maximisation (NPEM) algorithm Kisor, D. F.;Watling, S. M.;Zarowitz, B. J.;Jelliffe, R. W.
  30. Applied Mathematics and Computation v.45 Nonparametric EM algorithms for estimating prior distributions Schumitzky, A.
  31. Clin. Pharmacol. and ther. v.50 Gentamicin population pharmacokinetic models for low birth weight infants: using a new nonparametric algorithm Dodge, W. F.;Jellife, R. W.;Richardson, C. J.;McCleery, R. A.;Hokanson, J. A.
  32. Ther. Drug. Monit. v.14 Pharmacokinetic population parameters for aminoglycosides in cholecystitis patients Gill, M. A.;Okamoto, M. P.;Nakahiro, R. K.;Chin, A..lInagaki, K.;Sclar, D.
  33. Antimicrob. Agents Chemother. v.37 Comparison of population pharmacokinetic models for gentamicin in spinal cord-injured and able-bodies patients Gilman, T. M.;Brunnemann, S. R.;Segal, J. L.
  34. User manual for the nonparametric EM program for population pharmacokinetic modelling version 1. Jelliffe, R. W.;Schumitzky, A.
  35. Kor. J. Clin. Pharm. v.2 Clinical pharmacokinetics of gentamicin in appendicitis patients Choi, J. S.;Burm, J. P.;Lee, J. H.
  36. Yakhak Hoeji v.40 Clinical pharmacokimetics of gentamicin in gastrointestinal surgical patients Choi, J. S.;Moon, H. S.;Choi, I.;Burm, J. P.
  37. Antimicrob. Agents Chemother v.38 Comparison of aminoglycoside pharmacokinetics in asian, hispanic, and caucasian patients by using population pharmacokinetic methods Jhee, S. S.;Burm, J. P.;Gill, M. A.
  38. Yakhak Hoeji v.39 Population pharmacokinetics for gentamicin in American and Korean-American appendicitis patients using nonparametric expected maximum algorithm Brum, J. P.;Choi, J. S.;Jhee, S.;Gill, M. A.
  39. Ther. Drug. Monitor. v.5 Automated fluorescence polarization immunoassay for monitoring vancomycin Schwenzer, K. S.
  40. Ann. Intern. Med. v.94 Vancomycin therapy in patients with impsired renal function Moellering, R. C.
  41. Clin. Pharmacol. Ther. v.37 Vancomycin multi-dose kinetics in critically ill patients Narang, P. K.
  42. Clin. Pharmacol. Ther. v.50 Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance Marcias, W. L.
  43. Clin. Pharmacol. Ther. v.44 Altered vancomycin dose vs. serum concentration relationship in burn patients Garrdlts, J. C.;Peterie, J. D.
  44. Clin. Pharmacol. Ther. v.39 Vancomycin elimination in patients with burn injury Brater, D. C.
  45. J. Antimicdrob. Chemother. v.14 no.sup. Vancomycin pharmacokinetics in critically ill patients Guraud, J. J.
  46. Clin. Pharmacokinet. v.21 Individualizing gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring stategies Jelliffe, R. W.;Iglesiias, T.;Hurst, A.;Foo, K.;Rodriguez, J.
  47. Clin. Pharmacokinet. v.20 An updated comparison of drug dosing methods. Part Ⅲ: aminoglycoside antibiotics Erdmann, S. M.;Rodvold, K.;Pryka, R. D.
  48. Clin. Pharmacol. Ther. v.37 A Bayesian feedback method for aminoglycoside dosing Burton, M. E.;Brather, D. C.;Chen, P. S.;Say, R. B.;Hubber, J. J.;Vasko, M. R.
  49. Clin. Pharm. v.6 Comparison of four methods for predicting serum gentamicin concentrations in surgical patients with perforated or gangrenous appendicitis Hurst, A. K.;Iseri, K. T.;Gill, M. A.;Nofuchi, J. G.;Giljman, T. M.;Jelliffe, R. W.
  50. Clin. Pharm. v.12 Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies Fernandez D. G.